Janssen Biotech has entered a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the combination of the first CD38-directed cytolytic antibody daratumumab (DARZALEX®) and checkpoint inhibitor nivolumab (OPDIVO®) in Phase 1b/Phase 2